Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
BMS crushed Q3 goals and boosted its yearly forecast. New blockbusters like Opdivo and Eliquis cover losses from older generic drugs.
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.
